Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

37.40
-0.2000-0.53%
Post-market: 37.34-0.0600-0.16%19:30 EDT
Volume:1.60M
Turnover:59.67M
Market Cap:5.03B
PE:-10.74
High:38.14
Open:37.70
Low:36.86
Close:37.60
52wk High:49.70
52wk Low:10.46
Shares:134.37M
Float Shares:129.97M
Volume Ratio:0.66
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.47
PE(LYR):-18.16

Loading ...

Definium Therapeutics receives Breakthrough Therapy designation for DT120 ODT

TIPRANKS
·
Sep 08

Definium Therapeutics’ DT120 LSD Tablet Wins FDA Breakthrough Tag in Major Depressive Disorder After Phase 3 Study

Reuters
·
Sep 08

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (Lysergide) Orally Disintegrating Tablet (Odt) in Major Depressive Disorder (Mdd) Following Positive Phase 3 Results

THOMSON REUTERS
·
Sep 08

Definium Therapeutics Grants 88,900 Inducement Stock Options to New Hires

Reuters
·
Sep 01

Definium Therapeutics, Inc. put volume heavy and directionally bearish

TIPRANKS
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Aug 31

Definium Therapeutics (DFTX) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 31

Definium Therapeutics to Present at TD Cowen Novel Mechanisms in Neuropsychiatry Summit

Reuters
·
Aug 26

Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120

TIPRANKS
·
Aug 19

Definium Therapeutics Issues Inducement Stock Options to New Hires

TIPRANKS
·
Aug 19

Definium Therapeutics Initiated at Buy by B of a Securities

Dow Jones
·
Aug 18

Definium Therapeutics initiated with a Buy at BofA

TIPRANKS
·
Aug 18

Definium Therapeutics Issues Inducement Stock Options for 32,900 Shares to New Hires

Reuters
·
Aug 18

Definium Therapeutics price target raised to $66 from $57 at RBC Capital

TIPRANKS
·
Aug 17

Definium Therapeutics Price Target Raised to $55.00/Share from $50.00 by Maxim Group

Dow Jones
·
Aug 15

Analysts Conflicted on These Healthcare Names: Definium Therapeutics (DFTX), Ionis Pharmaceuticals (IONS) and Sutro Biopharma (STRO)

TIPRANKS
·
Aug 15

Definium Therapeutics Publishes Corporate Presentation Outlining DT120 ODT Clinical Development Pipeline in Mental Health Indications

Reuters
·
Aug 14

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

MT Newswires Live
·
Aug 13

RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13